Advanced Medical Solutions Grp PLC Total Voting Rights (8048U)
July 31 2020 - 7:29AM
UK Regulatory
TIDMAMS
RNS Number : 8048U
Advanced Medical Solutions Grp PLC
31 July 2020
31 July 2020
Advanced Medical Solutions Group plc
("AMS" or the "Group")
Total Voting Rights
In accordance with Disclosure and Transparency Rule 5.6.1, the
issued share capital of Advanced Medical Solutions Group plc as at
31 July 2020 comprises 215,277,568 ordinary shares of 5p each with
voting rights. There are no shares held in treasury.
The above figure may be used by shareholders as the denominator
for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest
in, the Company under the FCA's Disclosure and Transparency
Rules.
- Ends -
For further information, please visit www.admedsol.com or
contact:
Advanced Medical Solutions Group plc Tel: +44 (0) 1606
545508
Chris Meredith, Chief Executive Officer
Eddie Johnson, Chief Financial Officer
Consilium Strategic Communications Tel: +44 (0) 20 3709
5700
Mary-Jane Elliott / Matthew Neal / Olivia AMS@consilium-comms.com
Manser
Investec Bank PLC (NOMAD & Broker) Tel: +44 (0) 20 7597
5970
Daniel Adams / Patrick Robb / Gary Clarence
About Advanced Medical Solutions Group plc
AMS is a world-leading independent developer and manufacturer of
innovative and technologically advanced products for the global
surgical and woundcare markets, focused on quality outcomes for
patients and value for payers. AMS has a wide range of surgical
products including tissue adhesives, sutures, haemostats, and
internal fixation devices, which it markets under its brands
LiquiBand(R) , RESORBA(R) , and LiquiBandFix8(R) . AMS also
supplies wound care dressings such as silver alginates, alginates
and foams through its ActivHeal(R) brand as well as under white
label. In 2019, the Group made two acquisitions: Sealantis, an
Israeli medical device company with a patent-protected sealant
technology platform; and Biomatlante, an established developer and
manufacturer of innovative surgical biomaterial technologies based
in France.
AMS's products, manufactured in the UK, Germany, France, the
Netherlands, and the Czech Republic, are sold globally via a
network of multinational or regional partners and distributors, as
well as via AMS's own direct sales forces in the UK, Germany, the
Czech Republic and Russia. The Group has R&D innovation hubs in
the UK, Germany, France and Israel. Established in 1991, the Group
has approximately 700 employees. For more information, please see
www.admedsol.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
TVREAAXFDAPEEFA
(END) Dow Jones Newswires
July 31, 2020 08:29 ET (12:29 GMT)
Advanced Medical Solutions (LSE:AMS)
Historical Stock Chart
From Apr 2024 to May 2024
Advanced Medical Solutions (LSE:AMS)
Historical Stock Chart
From May 2023 to May 2024